Publications

Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

T Conroy, P Pfeiffer, V Vilgrain, A Lamarca, T Seufferlein, EM O’Reilly, ...

Patient-reported adverse events during neoadjuvant therapy in a phase 2 borderline resectable pancreatic cancer clinical trial (Alliance A021501)

RA Snyder, AC Dueck, B Fruth, Q Shi, JM Hubbard, JM Herman, ...

Patient-reported outcomes (PROs) and biomarkers in daNIS-2, a phase III study comparing NIS793 plus nab-paclitaxel/gemcitabine (NG) vs placebo plus NG in first-line (1L …

ZA Wainberg, T Macarulla, T Golan, M Ikeda, M Milella, J Taieb, L Wang, ...

Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048)

Basch E, Dueck AC, Mitchell SA, Mamon H, Weiser M, Saltz L, Gollub M, Rogak L, et al.

Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer

Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, … Park W, …

Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): Two cohorts B non-core homologous recombination …

W Park, C O'Connor, JF Chou, C Schwartz, AM Varghese, M Larsen, ...

Phase II trial of maximal ablative irradiation because of encasement (MAIBE) for patients with potentially resectable locally advanced pancreatic cancer.

M Reyngold, W Alice, EM O'Reilly, MI D'Angelica, JA Drebin, K Soares, ...

Physical activity in recurrent colon cancer: Cancer and Leukemia Group B/SWOG 80702 (Alliance)

Brown JC, Ma C, Shi Q, Zemla T, Couture F, Kuebler P, Kumar P, Tan B, et al.

Physical Activity in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance)

Brown JC, Ma C, Shi Q, Fuchs CS, Meyer J, Niedzwiecki D, Zemla T, Couture F, et al.

Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)

Wang QL, Ma C, Yuan C, Shi Q, Wolpin BM, Zhang Y, Fuchs CS, Meyer J, et al.

Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702

Lee S, Ma C, Shi Q, Kumar P, Couture F, Kuebler P, Krishnamurthi S, Lewis D, et al.

Preoperative Treatment of Locally Advanced Rectal Cancer

Schrag D, Shi Q, Weiser MR, Gollub MJ, Saltz LB, Musher BL, Goldberg J, Al Baghdadi T, et al.

Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma

Yu KH, Cockrum P, Surinach A, Lamarre N, Wang S, O'Reilly EM

Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer

Qunaj L, May MS, Neugut AI, Herzberg BO

PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal …

D Schrag, Q Shi, MR Weiser, MJ Gollub, LB Saltz, BL Musher, J Goldberg, ...

Radiation Therapy in Localized Pancreas Cancer: An Ongoing Conundrum

EM O'Reilly

Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (g …

V Chung, KA Guthrie, MJ Pishvaian, KA Reiss, AM Lowy, D Sohal, ...

Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden

Florou V, Floudas CS, Maoz A, Naqash AR, Norton C, Tan AC, Sokol ES, Frampton G, et al.

Registration-based biomarkers for neoadjuvant treatment response of pancreatic cancer via longitudinal image registration

JS Heiselman, BL Ecker, L Langdon-Embry, EM O’Reilly, MI Miga, ...

Sleep and cancer recurrence and survival in patients with resected Stage III colon cancer: findings from CALGB/SWOG 80702 (Alliance)

Lee S, Ma C, Shi Q, Meyers J, Kumar P, Couture F, Kuebler P, Krishnamurthi S, et al.

Sleep and cancer recurrence and survival in patients with resected Stage III colon cancer: findings from CALGB/SWOG 80702 (Alliance) Clinical Studies

S Lee, C Ma, Q Shi, J Meyers, P Kumar, F Couture, P Kuebler, ...

Smoking is Not Associated with Lung Metastasis in Pancreatic Cancer

May MS, Jamison JK, Wong W, Michel A, Raufi AG, Neugut AI, Manji GA

The Association between Proton Pump Inhibitors and the Effectiveness of CDK Inhibitors in HR+/HER- Advanced Breast Cancer Patients: A Systematic Review and Meta-Analysis

Chang YC, Song J, Chang Y, Huang CH, Sudan A, Chen PC, Chi KY

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

M Ducreux, GK Abou-Alfa, T Bekaii-Saab, J Berlin, A Cervantes, ...

The Onc Docs: Partnering with Black cancer patients for cancer education.

F Balogun, O Balogun

The prospect of universal coronavirus immunity: a characterization of reciprocal and non-reciprocal T cell responses against SARS-CoV2 and common human coronaviruses

Soni M, Migliori E, Fu J, Assal A, Chan HT, Pan J, Khatiwada P, Ciubotariu R, et al.

The prospect of universal coronavirus immunity: characterization of reciprocal and non-reciprocal T cell responses against SARS-CoV2 and common human coronaviruses

Soni MK, Migliori E, Fu J, Assal A, Chan HT, Pan J, Khatiwada P, Ciubotariu R, et al.

The SHARON trial: A study of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous stem cell rescue for metastatic pancreatic cancer with an inherited BRCA mutation.

KH Yu, CD Weekes, YBA Chen, JA Glazier, A Glazier, P Dahi, S Giralt, ...

Timing of Initiation of Palliative Chemotherapy in Asymptomatic Patients with Metastatic Pancreatic Cancer: An International Expert Survey and Case-Vignette Study

Augustinus S, van Laarhoven HWM, Cirkel GA, de Groot JWB, Groot Koerkamp B, Macarulla T, Melisi D, O'Reilly EM, et al.

Trial in progress: A phase 1, first-in-human, open-label, multicenter, dose-escalation and dose-expansion study of ASP3082 in patients with previously treated advanced solid …

AW Tolcher, W Park, JS Wang, AI Spira, PA Janne, HJ Lee, S Gill, ...

Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study.

W Park, EM O'Reilly, J Furuse, CP Li, DY Oh, R Garcia-Carbonero, G Roth, ...

1298P Extended overall survival results from the POLO study of active maintenance olaparib in patients with metastatic pancreatic cancer and a germline BRCA mutation

P Hammel, T Golan, M Reni, E Van Cutsem, TM Mercade, M Hall, JO Park, ...

1304P Characterizing the clinico-genomic landscape and outcomes of KRAS G12C mutated pancreas cancer

F Keane, W Park, A Varghese, F Balogun, K Yu, I El Dika, D Khalil, ...

508 Generalizability of predictive versus prognostic indicators from published transcriptomic associations with tumor response to immune checkpoint inhibition

D Bortone, A Monette, N Tschernia, A Cogdill, Y Najjar, RF Sweis, ...

656 Exploratory platform trial to evaluate immunotherapy combinations with chemotherapy for the treatment of patients with previously untreated metastatic pancreatic …

J Lyman, E O’Reilly, Z Wainberg, G Fisher, R Wolff, A Ko, M O’Hara, ...

Abstract C028: The lung pro-thrombotic niche drives cancer-associated thromboembolism and metastasis via extracellular vesicle ITGB2

S Lucotti, Y Ogitani, CM Kenific, L Bojmar, M Cioffi, P Lauritzen, H Molina, ...

Abstract CT126: a phase 2 trial of first-line AZD0171+ durvalumab and chemotherapy (CT) in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) and CD8+ T cell …

G O'Kane, T Macarulla, F Balogun, A Hollebecque, MJ Reilley, ...

Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis

NJ McCleary, S Zhang, C Ma, FS Ou, TM Bainter, AP Venook, ...

Alterations in somatic driver genes are associated with response to neoadjuvant FOLFIRINOX in patients with localized pancreatic ductal adenocarcinoma

BL Ecker, CM Court, QP Janssen, AJ Tao, MI D’Angelica, JA Drebin, ...

Associations of inflammatory biomarkers with survival among patients with stage III colon cancer (CALGB/SWOG 80702 [Alliance])

E Cheng, S Qian, AF Shields, EMC Feliciano, AB Nixon, AP Shergill, ...

Biomarker analysis from a phase II multi-institutional study of nivolumab in patients with advanced refractory biliary tract cancer

Kim DW, Kim YC, Kovari BP, Chung V, Alese OB, El-Rayes BF, Li D, Park W, et al.

Circulating KRAS variant-specific shedding and association with survival in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving …

JE Till, L McDaniel, SM Pfeiffer, DM Maurer, J Yu, C Spencer, JP Lyman, ...

Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer

Yu KH, Park J, Mittal A, Abou-Alfa GK, El Dika I, Epstein AS, Ilson DH, Kelsen DP, et al.

Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice

Park W, O'Connor CA, Bandlamudi C, Forman D, Chou JF, Umeda S, Reyngold M, Varghese AM, et al.

Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing

P Terraf, F Pareja, DN Brown, O Ceyhan-Birsoy, M Misyura, S Rana, ...

Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention

Giraldo NA, Drill E, Satravada BA, Dika IE, Brannon AR, Dermawan J, Mohanty A, Ozcan K, et al.

Concurrent Germline BRCA1/2 and Mismatch Repair Mutations in Young-Onset Pancreatic and Colorectal Cancer: The Importance of Comprehensive Germline and Somatic Characterization to Inform Therapeutic Options

Ozer M, Ranganathan M, Lecomte N, Schvartzman JM, Walch HS, Chatila WK, Hong J, Carlo MI, et al.

Distinct biosignatures associate with survival after chemoimmunotherapy in a randomized, three-arm phase II study in patients with metastatic pancreatic cancer.

LJ Padron, DM Maurer, MH O'Hara, EM O'Reilly, RA Wolff, ZA Wainberg, ...

Distinct KRAS Mutations are Enriched in Early-Stage Resected Pancreatic Ductal Adenocarcinoma

C McIntyre, A Grimont, V Aveson, K Seier, H Walch, A Pulvirenti, R Gelfer, ...

Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers.

AM Schram, K Goto, DW Kim, P Martin-Romano, SHI Ou, GM O'Kane, ...